Abiraterone, which is used with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body, is the first of six to 10 medicines that CivicaScript plans to initially develop to increase market competition and drive down price. The partnership between Lumicera and CivicaScript provides an opportunity to uniquely benefit payors and patients by furthering the shared commitment to transparency and drug affordability. This drug launch comes on the heels of Navitus Health Solutions announcing it has joined CivicaScript as a founding member.

“The lack of competition in the market is driving high-cost generic medicines, causing patients to ration or even entirely forgo their prescriptions,” said Brent Eberle, Chief Pharmacy Officer of Navitus and Lumicera and CivicaScript Board Member. “We partnered with CivicaScript to address this problem. Providing abiraterone through our specialty pharmacy is our first big stride in making affordable generic medicines accessible to millions of patients who rely on these drugs to live their best lives.”

CivicaScript was created in 2020 to bring affordable versions of common but high-priced generic medicines to market. The organization develops quality generic medicines through its trusted manufacturing partners, then works with like-minded payors, PBMs and pharmacies across the country to pass along the cost savings to their customers.

“This launch is just the beginning of our partnership with Lumicera and the critical work we’re doing to ensure patients come before profits,” Gina Guinasso, J.D., CivicaScript President. “Having abiraterone available to patients through Lumicera helps us advance our mission to make generic medicines affordable and available to everyone.”